title: Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol.
abstract: Various studies have reported that extracorporeal photopheresis is effective in producing meaningful responses in patients with Sézary syndrome. A single-center, 5-year retrospective analysis was performed on our patients with Sézary syndrome who received extracorporeal photopheresis using a novel protocol. Thirteen patients were treated with extracorporeal photopheresis consistently for a minimum of 2 months. All patients received a modified protocol of one treatment per week for 6 sessions, one session every 2 weeks for 6 sessions, and then one session per month. The overall response rate was 62%: two patients achieved a complete response and 6 patients achieved a partial response. The median time to response was 10 months. The 2- and 4-year predicted overall survivals were 82%. This study was limited by its retrospective nature and small sample size. Response and survival compare favorably with those of previous studies. Our modified treatment protocol appears to produce outcomes similar to the two-day protocol.
authors.affiliation: Division of Hematology and Medical Oncology, Department of Pathology, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, Parkville, Australia.
authors.forename: Suzanne
authors.initials: S
authors.lastname: Arulogun
authors.forename: H Miles
authors.initials: HM
authors.lastname: Prince
authors.forename: Peter
authors.initials: P
authors.lastname: Gambell
authors.forename: Stephen
authors.initials: S
authors.lastname: Lade
authors.forename: Gail
authors.initials: G
authors.lastname: Ryan
authors.forename: Eve
authors.initials: E
authors.lastname: Eaton
authors.forename: Christopher
authors.initials: C
authors.lastname: McCormack
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077610:Bexarotene; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D017893:Photopheresis; D012189:Retrospective Studies; D012751:Sezary Syndrome / Q000188:drug therapy* / Q000401:mortality; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D016898:Interferon-alpha; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene; D008727:Methotrexate